{"id":"https://openalex.org/W2301626401","doi":null,"title":"Current drug information: Apixaban superior to warfarin in preventing stroke or systemic embolism","display_name":"Current drug information: Apixaban superior to warfarin in preventing stroke or systemic embolism","publication_year":2012,"publication_date":"2012-05-01","ids":{"openalex":"https://openalex.org/W2301626401","mag":"2301626401"},"language":"en","primary_location":{"id":"mag:2301626401","doi":null,"is_oa":false,"landing_page_url":"http://search.informit.com.au/fullText;dn=338289835397631;res=IELHEA","pdf_url":null,"source":{"id":"https://openalex.org/S2764478071","display_name":"AJP: The Australian Journal of Pharmacy","issn_l":"0004-8399","issn":["0004-8399"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4363603738","host_organization_name":"Australian Pharmaceutical Publishing Company Ltd","host_organization_lineage":["https://openalex.org/P4363603738"],"host_organization_lineage_names":["Australian Pharmaceutical Publishing Company Ltd"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"AJP: The Australian Journal of Pharmacy","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059639429","display_name":"J. Thomas","orcid":"https://orcid.org/0000-0002-0461-6131","observed_orcids":["https://orcid.org/0000-0002-0461-6131"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jack Thomas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5059639429"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.24528496,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"93","issue":"1104","first_page":"93","last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":1.0},{"id":"https://openalex.org/keywords/warfarin","display_name":"warfarin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/stroke-prevention","display_name":"stroke prevention","score":0.6240000128746033},{"id":"https://openalex.org/keywords/systemic-embolism","display_name":"systemic embolism","score":0.9940000176429749},{"id":"https://openalex.org/keywords/atrial-fibrillation","display_name":"atrial fibrillation","score":0.9750000238418579},{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.7889999747276306},{"id":"https://openalex.org/keywords/vitamin-k-antagonists","display_name":"vitamin K antagonists","score":0.9549999833106995},{"id":"https://openalex.org/keywords/oral-anticoagulants","display_name":"oral anticoagulants","score":0.8379999995231628},{"id":"https://openalex.org/keywords/aspirin","display_name":"aspirin","score":0.8659999966621399}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9786179065704346},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.7972158193588257},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7935189008712769},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.7870457172393799},{"id":"https://openalex.org/C2777628954","wikidata":"https://www.wikidata.org/wiki/Q18216","display_name":"Aspirin","level":2,"score":0.7288187742233276},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.7172517776489258},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.5547479391098022},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5341310501098633},{"id":"https://openalex.org/C2777185221","wikidata":"https://www.wikidata.org/wiki/Q275466","display_name":"Embolism","level":2,"score":0.47587624192237854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43538662791252136},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4186156690120697},{"id":"https://openalex.org/C2993590494","wikidata":"https://www.wikidata.org/wiki/Q182338","display_name":"Vitamin k","level":2,"score":0.41778823733329773},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.40297752618789673},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.25755298137664795},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2301626401","doi":null,"is_oa":false,"landing_page_url":"http://search.informit.com.au/fullText;dn=338289835397631;res=IELHEA","pdf_url":null,"source":{"id":"https://openalex.org/S2764478071","display_name":"AJP: The Australian Journal of Pharmacy","issn_l":"0004-8399","issn":["0004-8399"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4363603738","host_organization_name":"Australian Pharmaceutical Publishing Company Ltd","host_organization_lineage":["https://openalex.org/P4363603738"],"host_organization_lineage_names":["Australian Pharmaceutical Publishing Company Ltd"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"AJP: The Australian Journal of Pharmacy","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1986899938","https://openalex.org/W2313910303","https://openalex.org/W2162508946","https://openalex.org/W3021210986","https://openalex.org/W2063551954","https://openalex.org/W2149388786","https://openalex.org/W2118857793","https://openalex.org/W2764069400","https://openalex.org/W7097203657","https://openalex.org/W2161602603"],"abstract_inverted_index":{"Vitamin":[0],"K":[1],"antagonists":[2],"are":[3],"highly":[4],"effective":[5],"in":[6,9,37,41],"preventing":[7],"stroke":[8,36],"patients":[10],"with":[11,43],"atrial":[12],"fibrillation":[13],"but":[14],"have":[15],"several":[16],"limitations.":[17],"Apixaban":[18],"is":[19],"a":[20,38],"novel":[21],"oral":[22],"direct":[23],"factor":[24],"Xa":[25],"inhibitor":[26],"that":[27],"has":[28],"been":[29],"shown":[30],"to":[31],"reduce":[32],"the":[33],"risk":[34],"of":[35],"similar":[39],"population":[40],"comparison":[42],"aspirin.":[44]},"counts_by_year":[],"updated_date":"2026-10-07T09:51:55.459714","created_date":"2016-06-24T00:00:00"}